T. Whiteside, S. Demaria, M. Rodriguez?ruiz, H. Zarour, and I. Melero, Emerging Opportunities and Challenges in Cancer Immunotherapy, Clinical Cancer Research, vol.22, issue.8, pp.1845-55, 2016.
DOI : 10.1158/1078-0432.CCR-16-0049

P. Sharma and J. Allison, Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, Cell, vol.161, issue.2, pp.205-219, 2015.
DOI : 10.1016/j.cell.2015.03.030

D. Munn and V. Bronte, Immune suppressive mechanisms in the tumor microenvironment, Current Opinion in Immunology, vol.39, issue.39, pp.1-6, 2015.
DOI : 10.1016/j.coi.2015.10.009

S. Van-der-burg, R. Arens, F. Ossendorp, T. Van-hall, and C. Melief, Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nature Reviews Cancer, vol.3, issue.4, pp.219-252, 2016.
DOI : 10.1038/ni1102-991

J. Pol, N. Bloy, A. Buqué, A. Eggermont, I. Cremer et al., Trial Watch: Peptide-based anticancer vaccines, OncoImmunology, vol.32, issue.4, p.974411, 2015.
DOI : 10.4161/onci.22616
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485775

M. Hossain and K. Wall, Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines, Vaccines, vol.31, issue.3, p.25, 2016.
DOI : 10.1080/07328303.2012.659364

M. Cheever, J. Allison, A. Ferris, O. Finn, B. Hastings et al., The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, Clinical Cancer Research, vol.15, issue.17, pp.5323-5360, 2009.
DOI : 10.1158/1078-0432.CCR-09-0737

S. Haen and H. Rammensee, The repertoire of human tumor-associated epitopes ??? identification and selection of antigens and their application in clinical trials, Current Opinion in Immunology, vol.25, issue.2, pp.277-83, 2013.
DOI : 10.1016/j.coi.2013.03.007

V. Lakshminarayanan, N. Supekar, J. Wei, D. Mccurry, A. Dueck et al., MUC1 vaccines, comprised of glycosylated or non?glycosylated peptides or tumor?derived MUC1, can circumvent immunoedit? ing to control tumor growth in MUC1 transgenic mice, PLoS ONE, vol.11, issue.1, p.145920, 2016.

P. Mitchell, N. Thatcher, M. Socinski, E. Wasilewska?tesluk, K. Horwood et al., Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses, Annals of Oncology, vol.26, issue.6, pp.1134-1176, 2015.
DOI : 10.1093/annonc/mdv104

A. Thomas and G. Giaccone, Why has active immunotherapy not worked in lung cancer?, Annals of Oncology, vol.26, issue.11, pp.2213-2233, 2015.
DOI : 10.1093/annonc/mdv323
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621028

G. Wurz, C. Kao, M. Wolf, and M. Degregorio, Tecemotide: an antigen? specific cancer immunotherapy. Hum Vaccines Immunother, pp.3383-93, 2014.
DOI : 10.4161/hv.29836
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514140

R. Ramlau, E. Quoix, J. Rolski, M. Pless, H. Lena et al., A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.3, issue.7, pp.735-779, 2008.
DOI : 10.1097/JTO.0b013e31817c6b4f

G. Rivalland, B. Loveland, and P. Mitchell, Update on Mucin-1 immunotherapy in cancer: a clinical perspective, Expert Opinion on Biological Therapy, vol.6, issue.6, pp.1773-87, 2015.
DOI : 10.1056/NEJMoa1414428

C. Rentzsch, S. Kayser, S. Stumm, I. Watermann, S. Walter et al., Evaluation of pre?existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen?specific T lymphocytes in peripheral blood mononuclear cells, Clin Cancer Res, vol.9, issue.12, pp.4376-86, 2003.

R. Boucherma, H. Kridane?miledi, R. Bouziat, M. Rasmussen, T. Gatard et al., HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses, The Journal of Immunology, vol.191, issue.2, pp.583-93, 2013.
DOI : 10.4049/jimmunol.1300483

H. Firat, F. Garcia?pons, S. Tourdot, S. Pascolo, A. Scardino et al., H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies, European Journal of Immunology, vol.90, issue.10, pp.3112-3133, 1999.
DOI : 10.1002/(SICI)1521-4141(199910)29:10<3112::AID-IMMU3112>3.0.CO;2-Q

S. Pascolo, N. Bervas, J. Ure, A. Smith, F. Lemonnier et al., ??2m Double Knockout Mice, The Journal of Experimental Medicine, vol.154, issue.12, pp.2043-51, 1997.
DOI : 10.1002/eji.1830260115

P. Rohrlich, HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus, International Immunology, vol.15, issue.6, pp.765-72, 2003.
DOI : 10.1093/intimm/dxg073

T. Tobery, S. Wang, X. Wang, M. Neeper, K. Jansen et al., A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay, Journal of Immunological Methods, vol.254, issue.1-2, pp.59-66, 2001.
DOI : 10.1016/S0022-1759(01)00397-0

D. Wreschner, M. Hareuveni, I. Tsarfaty, N. Smorodinsky, J. Horev et al., Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms, European Journal of Biochemistry, vol.55, issue.3, pp.463-73, 1990.
DOI : 10.1016/0092-8674(89)90910-0

P. Brossart, K. Heinrich, G. Stuhler, L. Behnke, V. Reichardt et al., Identification of HLA?A2?restricted T?cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies, Blood, vol.93, issue.12, pp.4309-4326, 1999.

L. Carmon, K. El?shami, A. Paz, S. Pascolo, E. Tzehoval et al., Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db???/??? ?? ??2 microglobulin (??2m) null mice transgenic for a chimeric HLA-A2.1/Db-??2 microglobulin single chain, International Journal of Cancer, vol.276, issue.3, pp.391-398, 2000.
DOI : 10.1002/(SICI)1097-0215(20000201)85:3<391::AID-IJC16>3.0.CO;2-V

B. Gückel, C. Rentzsch, M. Nastke, A. Marmé, I. Gruber et al., Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers, Journal of Cancer Research and Clinical Oncology, vol.3, issue.3, pp.265-74, 2006.
DOI : 10.1007/s00432-005-0064-6

K. Kokowski, U. Harnack, D. Dorn, and G. Pecher, Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer, Archivum Immunologiae et Therapiae Experimentalis, vol.53, issue.2, pp.141-146, 2008.
DOI : 10.4049/jimmunol.172.9.5249

M. Hebeisen, M. Allard, P. Gannon, J. Schmidt, D. Speiser et al., Iden? tifying individual T cell receptors of optimal avidity for tumor antigens, Front Immunol, vol.6, 2015.

D. Cole, B. Laugel, M. Clement, D. Price, L. Wooldridge et al., The molecular determinants of CD8 co-receptor function, Immunology, vol.118, issue.2, pp.139-187, 2012.
DOI : 10.1182/blood-2011-01-328781

L. Wooldridge, H. Van-den-berg, M. Glick, E. Gostick, B. Laugel et al., Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface, Journal of Biological Chemistry, vol.163, issue.30, pp.27491-501, 2005.
DOI : 10.1016/S0167-5699(98)01299-7

V. Dutoit, P. Guillaume, M. Ayyoub, C. Hesdorffer, I. Luescher et al., Decreased Binding of Peptides-MHC Class I (pMHC) Multimeric Complexes to CD8 Affects Their Binding Avidity for the TCR But Does Not Significantly Impact on pMHC/TCR Dissociation Rate, The Journal of Immunology, vol.170, issue.10, pp.5110-5117, 2003.
DOI : 10.4049/jimmunol.170.10.5110

M. Pittet, V. Rubio?godoy, G. Bioley, P. Guillaume, P. Batard et al., ??3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells, The Journal of Immunology, vol.171, issue.4, pp.1844-1853, 2003.
DOI : 10.4049/jimmunol.171.4.1844

S. Farkona, E. Diamandis, and I. Blasutig, Cancer immunotherapy: the beginning of the end of cancer?, BMC Medicine, vol.72, issue.6230, p.73, 2016.
DOI : 10.1158/0008-5472.CAN-11-1620

J. Gulley, P. Mulders, P. Albers, J. Banchereau, M. Bolla et al., Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm, OncoImmunology, vol.30, issue.5, p.1107698, 2016.
DOI : 10.1038/nrc3820

L. Butterfield, Cancer vaccines, BMJ, vol.350, issue.apr22 14, p.988, 2015.
DOI : 10.1136/bmj.h988

N. Mcgranahan, A. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.7, issue.5, pp.1463-1472, 2016.
DOI : 10.1038/nprot.2012.037

A. Kirilovsky, F. Marliot, E. Sissy, C. Haicheur, N. Galon et al., Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients, International Immunology, vol.28, issue.8, pp.373-82, 2016.
DOI : 10.1093/intimm/dxw021

H. Kissick and M. Sanda, The role of active vaccination in cancer immunotherapy: lessons from clinical trials, Current Opinion in Immunology, vol.35, pp.15-22, 2015.
DOI : 10.1016/j.coi.2015.05.004

C. Britten, S. Janetzki, S. Van-der-burg, C. Huber, M. Kalos et al., Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunology, Immunotherapy, vol.77, issue.9, pp.15-22, 2011.
DOI : 10.1002/cyto.a.20916

C. Britten, S. Janetzki, L. Ben?porat, T. Clay, M. Kalos et al., Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium, Cancer Immunology, Immunotherapy, vol.57, issue.Suppl 1, pp.1701-1714, 2009.
DOI : 10.1002/cyto.a.20583

A. Vitiello, D. Marchesini, J. Furze, L. Sherman, and R. Chesnut, Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex, Journal of Experimental Medicine, vol.173, issue.4, pp.1007-1022, 1991.
DOI : 10.1084/jem.173.4.1007

H. Nojima, K. Kanou, K. Kamiya, K. Atsuda, H. Umeyama et al., Dynamic Influence of the Two Membrane-Proximal Immunoglobulin-Like Domains upon the Peptide-Binding Platform Domain in Class I and Class II Major Histocompatibility Complexes: Normal Mode Analysis, CHEMICAL & PHARMACEUTICAL BULLETIN, vol.57, issue.11, pp.1193-1202, 2009.
DOI : 10.1248/cpb.57.1193

E. Choi, M. Palmowski, J. Chen, and V. Cerundolo, The use of chimeric A2Kb tetramers to monitor HLA A2 immune responses in HLA A2 transgenic mice, Journal of Immunological Methods, vol.268, issue.1, pp.35-41, 2002.
DOI : 10.1016/S0022-1759(02)00198-9